Attendee search 

20/20 GeneSystems, headquartered in Rockville, Maryland (outside of Washington, D.C.), is a revenue stage diagnostics company that uses machine learning algorithms to greatly improve the accuracy of laboratory tests for the early detection of cancer and other diseases.  In the most recent calendar year our revenues grew to over $2 million aided by several COVID-19 tests that we are successfully commercializing. 

Our multi-cancer early detection blood test (www.OneTest.Ai) measures tumor antigens and uses a machine learning algorithm powered by outcome data from over 230,000 individuals tested in real-world screening settings.  OneTest is a highly accessible and affordable pre-test that can be followed up with more expensive and specific circulating tumor DNA tests such as those being developed by Grail and Thrive Earlier Detection.  (Those companies were recently acquired for $8 billion and $2 billion respectively.)      

20/20’s institutional investors include Ping An, one of the largest digital health and insurance companies in China, and several well-regarded American funds.   We are working to an initial public offering in 2021 and are now lining up IPO “crossover” investors.

A biotech company headquartered in China with clinically validated integrated platform for drug discovery and development.  We focus on oncology and inflammatory disease. There are four projects on Phase I clinical stage.